Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a focus on addressing infectious diseases and other significant unmet medical needs.

Its portfolio and development programs have included treatments for infectious diseases, central nervous system conditions, pain and other therapeutic areas. Shionogi is known for products such as Xofluza (baloxavir marboxil), an influenza treatment, and Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat bacterial infections. The company has also developed Xocova (ensitrelvir), an oral treatment for COVID-19 approved in Japan.

Shionogi serves the Japanese market and conducts international business through overseas subsidiaries, research activities and partnerships with pharmaceutical companies in other regions. Its products and research collaborations have supported commercialization in North America, Europe and other global markets, while the company continues to emphasize research-based drug discovery and infectious-disease innovation.

Key Stats

• Today's Range: $17.95 to $17.95
• 50-Day Range: $16.39 to $18.91
• 52-Week Range: $14.25 to $26.00
• Volume: N/A
• Average Volume: 1,702 shs
• Market Capitalization: N/A
• P/E Ratio: 0.20
• Dividend Yield: 106.40%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

Shionogi & Co., Ltd. scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd..

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. is 0.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. is 0.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 193.11.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 6.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shionogi & Co., Ltd. pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.

Percentage Held by Institutions

22.59% of the stock of Shionogi & Co., Ltd. is held by institutions.

Company Calendar

• Today: 10/13/2026
• Next Earnings (Estimated): 10/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SGIOF
• CIK: 1281721
• Web: shionogi.com
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,690
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A